136 related articles for article (PubMed ID: 3509139)
1. Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study.
McNamara PJ; Foster TS; Digenis GA; Patel RB; Craig WA; Welling PG; Rapaka RS; Prasad VK; Shah VP
Pharm Res; 1987 Apr; 4(2):150-3. PubMed ID: 3509139
[TBL] [Abstract][Full Text] [Related]
2. Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men.
Waller ES; Crismon ML; Smith RV; Bauza MT; Doluisio JT
Biopharm Drug Dispos; 1988; 9(2):211-8. PubMed ID: 3370308
[TBL] [Abstract][Full Text] [Related]
3. Assessment of pharmaceutical quality of furosemide tablets from multinational markets.
Qureshi SA; McGilveray IJ
Drug Dev Ind Pharm; 1998 Nov; 24(11):995-1005. PubMed ID: 9876554
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of seven furosemide tablets in man.
Straughn AB; Wood GC; Raghow G; Meyer MC
Biopharm Drug Dispos; 1986; 7(2):113-20. PubMed ID: 3708119
[TBL] [Abstract][Full Text] [Related]
5. Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations.
Rasool BK; Fahmy SA; Galeel OW
Pak J Pharm Sci; 2012 Oct; 25(4):815-22. PubMed ID: 23009999
[TBL] [Abstract][Full Text] [Related]
6. In vivo/in vitro correlations for four differently dissolving ketorolac tablets.
Gordon MS; Chowhan Z
Biopharm Drug Dispos; 1996 Aug; 17(6):481-92. PubMed ID: 8866039
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence evaluation of two brands of furosemide 40 mg tablets (Salurin and Lasix) in healthy human volunteers.
Najib N; Idkaidek N; Beshtawi M; Bader M; Admour I; Alam SM; Zaman Q; Dham R
Biopharm Drug Dispos; 2003 Sep; 24(6):245-9. PubMed ID: 12973821
[TBL] [Abstract][Full Text] [Related]
9. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
[TBL] [Abstract][Full Text] [Related]
10. Prolonged-release hydroxypropyl methylcellulose matrix tablets of furosemide for administration to dogs.
Smal J; Marvola M; Liljequist C; Happonen I
J Vet Pharmacol Ther; 1996 Dec; 19(6):482-7. PubMed ID: 8971678
[TBL] [Abstract][Full Text] [Related]
11. In vivo pharmacokinetic-pharmacodynamic relationship and in vitro equivalence of two oral furosemide tablet formulations.
Cuadrado A; Rodríguez Gascón A; Hernández RM; Castilla AM; de la Maza A; Yánez C; López de Ocáriz A; Solinís MA; Pedraz JL
Arzneimittelforschung; 2003; 53(5):321-9. PubMed ID: 12854359
[TBL] [Abstract][Full Text] [Related]
12. A bioequivalence study of two products of furosemide tablets.
Awad R; Arafat T; Saket M; Saleh M; Gharaibeh M; Zmeili S; Sallam E; Shubair M; Qobrosi S
Int J Clin Pharmacol Ther Toxicol; 1992 Jan; 30(1):18-23. PubMed ID: 1551740
[TBL] [Abstract][Full Text] [Related]
13. Bioavailability and pharmacokinetics of furosemide marketed in Thailand.
Kaojarern S; Poobrasert O; Utiswannakul A; Kositchaiwat U
J Med Assoc Thai; 1990 Apr; 73(4):191-7. PubMed ID: 2394955
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers.
Kim JE; Ki MH; Yoon IS; Cho HJ; Kim RS; Tae Kim G; Kim DD
Clin Ther; 2014 Feb; 36(2):273-9. PubMed ID: 24529292
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of an oral frusemide/amiloride combination tablet.
Brooks SG; Christie RB; Roche J; Fairhead AP; Muirhead D; Townsend HA; Shaw HL
Curr Med Res Opin; 1984; 9(2):141-6. PubMed ID: 6399890
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability and diuretic effect of furosemide following administration of tablets and retarded capsules to human subjects.
Yagi N; Kiuchi T; Satoh H; Terashima Y; Kenmotsu H; Sekikawa H; Takada M
Biol Pharm Bull; 1996 Apr; 19(4):616-22. PubMed ID: 8860970
[TBL] [Abstract][Full Text] [Related]
17. The pharmaceutical and biological availability of commercial preparations of furosemide.
Stüber W; Mutschler E; Steinbach D
Arzneimittelforschung; 1982; 32(6):693-7. PubMed ID: 6889429
[TBL] [Abstract][Full Text] [Related]
18. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
Otsuka K; Wagner C; Selen A; Dressman J
J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
[TBL] [Abstract][Full Text] [Related]
19. Dosage variability of veterinary drug products, containing furosemide, linked to tablet splitting.
Maggi L; Friuli V; Perugini P; Musitelli G; Venco L
Open Vet J; 2021; 11(3):471-482. PubMed ID: 34722213
[TBL] [Abstract][Full Text] [Related]
20. Determination of bioequivalence of two furosemide preparations; the effect of high doses of furosemide on some pharmacokinetic parameters.
Wolf-Coporda A; Lovrić Z; Huić M; Francetić I; Vrhovac B; Plavsić F; Skreblin M
Int J Clin Pharmacol Res; 1996; 16(4-5):83-8. PubMed ID: 9172005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
